Bonraybio (邦睿生技-創) Chairman Hsu Zhen-teng announced a significant capital expansion plan during the company's annual general shareholders' meeting on May 20, 2026. Backed by sustained revenue and net profit growth, Bonraybio will execute a capital increase following the close of H2 2026, boosting its paid-in capital from NT$170 million to over NT$300 million. The influx of capital will fund international clinical pipelines, global commercial scale-ups, and strategic R&D allocations.

Financial Performance and Dividend Distributions

Bonraybio delivered a strong financial rollout for the early months of fiscal year 2026, reporting a Q1 EPS of NT$0.97. Consolidated revenue for the first four months surpassed the critical threshold to reach NT$113 million, representing a 15% year-over-year increase.

The shareholders' meeting approved the 2025 earnings distribution plan, passing a NT$1.50 stock dividend alongside a NT$0.75 stock dividend via capital surplus capitalization, bringing the total stock dividend allocation to NT$2.25 per share. When combined with the NT$1.50 cash dividend distributed in April 2026, Bonraybio’s total dividend payout for the year reached NT$3.75 per share.

AI Reproductive Medicine Market Drivers

Hsu noted that structural macro trends—including delayed marriage timelines, elevated stress profiles, and shifting modern lifestyles—have led to a global rise in clinical infertility rates. This demographic shift is driving international demand for advanced assisted reproductive technology (ART) and highly standardized, precision screening diagnostics.

Bonraybio's core strategic focus centers on developing proprietary AI-powered intelligent reproductive testing platforms designed around four design pillars: Simplicity, Speed, Standardization, and Intelligence.

The company's commercial anchor product, an AI-driven automated sperm quality analysis system, reduces testing workflows down to just 1 minute. The edge-AI optics platform computes multi-dimensional reproductive metrics rapidly, minimizing human interpretation errors and enhancing clinical throughput inside embryology labs. Bonraybio plans to leverage its post-funding capital architecture to deepen its AI algorithms, broaden its intelligent medical hardware pipeline, and drive institutional adoption across global fertility networks and reproductive medical centers.

Resource: 需求激增 邦睿擴AI生殖醫材布局